Carbon To Carbon Unsaturation Patents (Class 514/560)
  • Patent number: 10729637
    Abstract: The present disclosure relates to compositions suitable as leave-in hairstyling compositions comprising (a) a first polysaccharide comprising inulin; (b) a second polysaccharide comprising carrageenan; (c) a third polysaccharide; and (d) a humectant. The compositions as leave-on hair styling do not require synthetic film-forming polymers nor do they require silicones. The leave-on hair styling compositions are particularly useful in methods for imparting durable styling or shaping benefits to hair.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 4, 2020
    Assignee: L'OREAL
    Inventors: Sana Ghani, Aziza Khader Suleiman, Vanessa Decarlo
  • Patent number: 10682397
    Abstract: Disclosed herein are novel methodologies of treating fragile X syndrome and related disorders by inhibiting mGlu5-relevant signaling pathways via the reduction of ?-arrestin2 protein levels or the diminution of mGlu5 and ?-arrestin2 protein interactions.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: June 16, 2020
    Assignees: Massachusetts Institute of Technology, Duke University
    Inventors: Benjamin David Auerbach, Mark Firman Bear, Laura Jane Stoppel, Robert J. Lefkowitz
  • Patent number: 10668041
    Abstract: The invention provides compositions and methods for treatment of epilepsy in an animal. In one embodiment, a method for treating epilepsy in a companion animal can comprise administering to the companion animal a food composition comprising a medium chain triglyceride (MCT), wherein the MCT is present in the food composition in an effective amount for reducing or preventing seizures when the food composition is administered to the companion animal.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 2, 2020
    Assignee: Societe des Produits Nestle SA
    Inventors: Yuanlong Pan, Brian Michael Zanghi, Jean-Christophe Bouthegourd
  • Patent number: 10653703
    Abstract: The present invention relates to a polyunsaturated fatty acid composition comprising Omega-3 fatty acids, 17-HDHA and 18-HEPE. The composition can furthermore comprise DPA and/or an acceptable carrier and can be present in a capsule or other suitable dosage unit. The invention also relates to the process of obtaining the composition and methods for using same.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: May 19, 2020
    Assignee: Solutex NA LLC
    Inventors: Charles Nicholas Serhan, Fernando Moreno Egea, Joan Clària Enrich
  • Patent number: 10633324
    Abstract: This disclosure provides compounds, pharmaceutical compositions, and methods of use for the prevention and treatment of inflammatory diseases or degenerative diseases including neurodegenerative diseases. Embodiments of the present disclosure provide compounds related to very long chain polyunsaturated fatty acids, pharmaceutical compositions containing the provided compounds, and methods of treating a subject with a condition or disease using provided compounds or pharmaceutical compositions.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: April 28, 2020
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Nicolas G. Bazan, Nicos A. Petasis
  • Patent number: 10576051
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: March 3, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10576053
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Torr or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: March 3, 2020
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10537543
    Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and to methods of using same to treat a variety of conditions and disorders.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 21, 2020
    Assignee: DS Biopharma Limited
    Inventors: Mehar Manku, John Climax, David Coughlan, James Dunne
  • Patent number: 10485779
    Abstract: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 26, 2019
    Assignee: Calanus AS
    Inventors: Jan Raa, Gunnar Rorstad, Kurt Steinar Tande
  • Patent number: 10485784
    Abstract: An orally administrable composition for treating or reducing damage to connective tissue or for treating or reducing inflammatory symptoms associated with damage to connective tissue includes a synergistic combination of: (i) avocado/soybean unsaponifiables; and (ii) lipoic acid, or a salt or derivative thereof. Methods for treating or reducing damage to connective tissue, for treating or reducing inflammatory symptoms associated with damage to connective tissue, or for reducing levels of one or more inflammatory mediators in connective tissue include administering the orally administrable composition to an avian or mammalian subject.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: November 26, 2019
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Carmelita Frondoza, Todd R. Henderson, Reinhard Grzanna
  • Patent number: 10449172
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: October 22, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
  • Patent number: 10350186
    Abstract: The present invention is based on the discovery that parenteral nutrition (PN) induced liver disease, e.g. fatty liver disease, can be prevented and even reversed by administration of primarily omega-3-fatty acid with PN rather than the administration of the standard intravenous lipid emulsions that contain primarily plant derived omega-6 fatty acid. Thus, the present invention provides a method for treating or preventing liver disease in a human patient obtaining nutritional support through PN. The method comprises intravenous administration of an effective amount of an omega-3-fatty acid emulsion to the patient, wherein the patient is not administered phytosterols or plant derived fatty acids, e.g. omega-6 fatty acids derived from a plant source, and wherein the administration of the omega-3-fatty acid emulsion to the patient is for a period greater than three weeks. Preferably, the administration is for a period of greater than six weeks.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: July 16, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Mark Puder, Kathleen M. Gura
  • Patent number: 10265290
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: April 23, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 10258589
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 16, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 10258588
    Abstract: The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (CR) compounds, wherein the lipids are cell-free and the CR compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair. Also, the invention pertains to a method for the therapeutic or cosmetic treatment of a mammal comprising the administration of the composition of the invention and preferably injecting the composition while withdrawing the injection needle until the tissue area of interest is treated.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: April 16, 2019
    Assignee: PB&B SA
    Inventors: Anthony Youri Aho, Raghunathan Sandeep
  • Patent number: 10258587
    Abstract: The present invention is directed to a method of preventing or treating a gastrointestinal condition in a subject, that includes administering one or more branched chain fatty acid to the subject under conditions effective to prevent or treat the gastrointestinal condition in the subject. The present invention is also directed to methods of promoting gastrointestinal health in a subject and propagation of probiotic organisms. Also disclosed is a formulation which includes one or more branched chain fatty acid and an aqueous phase emulsified with the one or more branched chain fatty acids, where the formulation includes over 25 wt % of the one or more branched chain fatty acid.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: April 16, 2019
    Assignee: Cornell University
    Inventors: James Thomas Brenna, Rinat Ran-Ressler
  • Patent number: 10251856
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: April 9, 2019
    Assignees: DEAKIN UNIVERSITY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
    Inventors: Steve Cheung, Wah Chin Boon
  • Patent number: 10226443
    Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 12, 2019
    Assignees: New York University, Memorial Sloan-Kettering Cancer Center, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (Fisabio)
    Inventors: Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson, Sergei B. Koralov
  • Patent number: 10208270
    Abstract: The present invention relates to the recombinant manufacture of polyunsaturated fatty acids. Specifically, it relates to acyltransferase polypeptides, polynucleotides encoding said acyltransferases as well as vectors, host cells, non-human transgenic organisms containing said polynucleotides. Moreover, the present invention contemplates methods for the manufacture of polyunsaturated fatty acids as well as oils obtained by such methods.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: February 19, 2019
    Assignee: BASF Plant Science Company GmbH
    Inventors: Toralf Senger, Laurent Marty, Sten Stymne, Jenny Lindberg Yilmaz, Johnathan A. Napier, Olga Sayanova, Richard Haslam, Ruiz Lopez Noemi
  • Patent number: 10188622
    Abstract: Disclosed is a composition including a fish oil and a juice in an oil-in-water emulsion for use in treatment and post-treatment of cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 29, 2019
    Assignee: Smartfish AS
    Inventor: Janne Sande Mathisen
  • Patent number: 10154979
    Abstract: Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-?-oxidizable fatty acid analoges such as tetradecylthioacetic acid.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: December 18, 2018
    Assignee: SCIADONICS, INC.
    Inventors: Jan Remmereit, Alvin Berger
  • Patent number: 10130574
    Abstract: Provided are compositions useful for inhibiting oxidation of unsaturated fats comprising an antioxidant compound of Formula I: wherein R, R1, R2, R3, R4, R5 and R6 are as defined herein.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 20, 2018
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Cassie Fhaner, Kinjalbahen Joshi, Yujing Tan
  • Patent number: 10130603
    Abstract: Provided are methods and compositions for improving kidney function and for the treatment or prophylaxis of kidney disease in dogs.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: November 20, 2018
    Assignee: Colgate-Palmolive Company
    Inventor: Dennis Jewell
  • Patent number: 10125078
    Abstract: The present invention relates to the NSAID derivatives of omega-3 fatty acids as gamma secretase modulators and their use in treating Alzheimer's disease, hypertriglyceridemia, and cardiovascular disease by reducing triglycerides, and for use as anti-inflammatory agents.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: November 13, 2018
    Assignee: Jiva Pharma Inc.
    Inventor: Om P Goel
  • Patent number: 10105340
    Abstract: Provided are: a composition containing 96-99 area % of eicosapentaenoic acid alkyl ester, the composition having an arachidonic acid alkyl ester content of 0.7 area % or less, and an eicosapentaenoic-acid-alkyl-ester mono-trans isomer content of 2.5 area % or less; and a method for producing a composition containing a high concentration of eicosapentaenoic acid alkyl ester, the method including performing precision distillation on a composition containing eicosapentaenoic acid alkyl ester, obtained by alkyl esterification of a raw material oil containing eicosapentaenoic acid, under a vacuum of 0.2 Ton or lower and a temperature of 190° C. or lower in the entire column, and performing a concentration treatment on the precision-distilled composition using chromatography.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: October 23, 2018
    Assignees: NIPPON SUISAN KAISHA, LTD., MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Nobushige Doisaki, Shingo Arato, Takuro Fukae
  • Patent number: 10071071
    Abstract: A method for influencing behavior in young, adult or aged pet animals which comprises systemically administering a behavior influencing quantity of an omega-3 fatty acid or mixture of omega-3 fatty acids.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: September 11, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Steven Curtis Zicker, Chadwick E. Dodd, Dennis Jewell, Dale A. Fritsch
  • Patent number: 10046001
    Abstract: Compositions, kits, and methods for reducing intraocular pressure (IOP) in a subject (e.g., human) include at least one naturally occurring or synthesized version or analog thereof of a lipid (e.g., a phosphoserine, a phosphocholine, a psychosine or other glycolipid) that is endogenous to non-glaucomatous aqueous humor in a subject and that lowers IOP in the subject, in a therapeutically effective amount for promoting aqueous outflow through TM in at least one eye of the subject and reducing IOP in the subject. The compositions can be used for, e.g., treating glaucomas, including, for example, primary open angle glaucoma (POAG) and normal tension glaucoma (NTG).
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: August 14, 2018
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Richard K. Lee, Sanjoy K. Bhattacharya
  • Patent number: 9962354
    Abstract: The present disclosure relates to methods and compositions for suppressing the growth of microorganisms on selected areas of the skin for an extended period of time, such as one hour, twenty four hours, seventy two hours, or longer. An area of the skin is selected for the suppression of the growth of microorganisms and a microorganism growth suppressing agent is topically applied to the selected area of the skin. The microorganism growth suppressing agent may be comprised in a pharmacologically acceptable vehicle such as an emulsion or soap. The microorganism growth suppressing agent comprises free conjugated fatty acid such as conjugated linoleic acid.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: May 8, 2018
    Inventor: David G. Changaris
  • Patent number: 9925163
    Abstract: The present invention relates generally to methods for the treatment and/or prophylaxis of neurological diseases and disorders involving administration of trans 10-HDA. In particular, the methods of the present invention are useful in the treatment and/or prophylaxis of acquired or progressive neurodevelopmental disorders and conditions in mammals. More particularly, methods are taught herein for the treatment and/or prophylaxis of diseases and disorders such as autism spectrum disorders.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: March 27, 2018
    Assignees: DEAKIN UNIVERSITY, THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH
    Inventors: Steve Cheung, Wah Chin Boon
  • Patent number: 9884035
    Abstract: Methods and compositions for hydrating cats. Cats fed diets containing certain amounts and ratios of arachidonic acid and eicosapentaenoic acid will be sufficiently hydrated and at reduced risk for development of urinary stones, feline idiopathic cystitis, or FLUTD.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 6, 2018
    Assignee: Hill's Pet Nutrition, Inc.
    Inventors: Jeffrey Brockman, Dennis Jewell
  • Patent number: 9884820
    Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: February 6, 2018
    Assignee: Board of Regents of the University of Texas System
    Inventors: Steven L. McKnight, Andrew A. Pieper, Joseph M. Ready, Jef K. De Brabander
  • Patent number: 9877941
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: January 30, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 9879258
    Abstract: The present invention relates to modulators, in particular inhibitors, of TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in mammal. The present invention further relates to screening methods in order to identify these modulators, the use of modulators as identified in the diagnosis of these diseases, as well as kits, comprising materials for performing the methods according to the present invention.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: January 30, 2018
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Mauricio Berriel Diaz, Stephan Herzig, Kilian Friedrich, Allan Jones
  • Patent number: 9855240
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: January 2, 2018
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9844517
    Abstract: Disclosed are nutritional formulations including predigested fats that can be administered to preterm infants, infants, toddlers, and children for improving tolerance, digestion, and absorption of nutrients and for reducing the incidence of necrotizing enterocolitis, colic, and short bowel syndrome. The predigested fats include fatty acid-containing monoglycerides and/or a fatty acid component.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: December 19, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Chron-Si Lai, John B. Lasekan, Gary E. Katz, Christopher T. Cordle
  • Patent number: 9814733
    Abstract: In various embodiments, the present invention provides compositions comprising eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof. In other embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising co-administering to a subject in need thereof eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof.
    Type: Grant
    Filed: December 31, 2013
    Date of Patent: November 14, 2017
    Assignee: A,arin Pharmaceuticals Ireland Limited
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9795640
    Abstract: A method for treating obesity, insulin sensitivity, and related conditions involves administering to the subject a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE). A composition includes a bacterium for overexpressing a N-acyl-phosphatidylethanolamine (NAPE) and/or a N-acylethanolamine (NAE); and an ingestible vehicle in which the bacterium is provided.
    Type: Grant
    Filed: September 19, 2012
    Date of Patent: October 24, 2017
    Assignee: Vanderbilt University
    Inventors: Sean S. Davies, Zhongyi Chen, Lilu Guo, Yongqin Zhang
  • Patent number: 9790162
    Abstract: The present invention provides a chromatographic separation process for recovering a polyunsaturated fatty acid (PUFA) product, from a feed mixture, which process comprises introducing the feed mixture to a simulated or actual moving bed chromatography apparatus having a plurality of linked chromatography columns containing, as eluent, an aqueous alcohol, wherein the apparatus has a plurality of zones comprising at least a first zone and a second zone, each zone having an extract stream and a raffinate stream from which liquid can be collected from said plurality of linked chromatography columns, and wherein (a) a raffinate stream containing the PUFA product together with more polar components is collected from a column in the first zone and introduced to a nonadjacent column in the second zone, and/or (b) an extract stream containing the PUFA product together with less polar components is collected from a column in the second zone and introduced to a nonadjacent column in the first zone, said PUFA product be
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: October 17, 2017
    Assignee: BASF PHARMA (CALLANISH) LIMITED
    Inventors: Adam Kelliher, Angus Morrison, Anil Oroskar, Rakesh Vikraman Nair Rema, Abhilesh Agarwal
  • Patent number: 9707200
    Abstract: The present invention provides a metabolism improving agent comprising an oxo fatty acid having 18 carbon atoms and a carbonyl group at the 10- or 12-position, and/or a hydroxy fatty acid having 18 carbon atoms and a hydroxyl group at the 10- and/or 12-position(s), and use of the metabolism improving agent as a food, a pharmaceutical product and the like.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: July 18, 2017
    Assignees: Kyoto University, Nitto Pharmaceutical Industries, Ltd.
    Inventors: Jun Ogawa, Shigenobu Kishino, Si-Bum Park, Teruo Kawada, Nobuyuki Takahashi, Tsuyoshi Goto, Hidekazu Kim, Tatsuya Sugawara, Takashi Hirata, Yasunori Yonejima
  • Patent number: 9701947
    Abstract: The invention relates generally to methods and compositions concerning desaturase enzymes that modulate the number and location of double bonds in long chain poly-unsaturated fatty acids (LC-PUFA's). In particular, the invention relates to methods and compositions for improving omega-3 fatty acid profiles in plant products and parts using desaturase enzymes and nucleic acids encoding for such enzymes. In particular embodiments, the desaturase enzymes are Primula ?6-desaturases. Also provided are improved soybean oil compositions having SDA and a beneficial overall content of omega-3 fatty acids relative to omega-6 fatty acids.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 11, 2017
    Assignee: Monsanto Technology LLC
    Inventors: Virginia Ursin, Byron Froman, Jennifer Simmons, Thomas J. LaRosa, Fenggao Dong, Steven Screen
  • Patent number: 9700534
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: July 11, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Patent number: 9700537
    Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.
    Type: Grant
    Filed: February 14, 2017
    Date of Patent: July 11, 2017
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito
  • Patent number: 9675574
    Abstract: The invention relates to a composition comprising a combination of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The composition can be used for enhancing the activity of chemotherapy or radiotherapy and/or in the prevention or reduction of side effects caused by the chemotherapy or radiotherapy in a patient ill with cancer, the composition being intended for administration to the patient prior to the commencement of a cycle of chemotherapy or radiotherapy.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: June 13, 2017
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Ewald Schlotzer, Barbara Krampitz, Ulrich Suchner
  • Patent number: 9662307
    Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 30, 2017
    Assignee: The Regents of the University of Colorado
    Inventor: Joseph S. Zakrzewski
  • Patent number: 9616048
    Abstract: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: April 11, 2017
    Assignee: Board of Regents of The University of Texas System
    Inventors: Steven L. McKnight, Andew A. Pieper, Joseph M. Ready, Jef K. De Brabander, Jeffrey M. Zigman
  • Patent number: 9604899
    Abstract: The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: March 28, 2017
    Assignee: Diffusion Pharmaceuticals LLC
    Inventors: John L. Gainer, Raymond C. Grabiak
  • Patent number: 9585887
    Abstract: The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: March 7, 2017
    Assignee: Tangent Reprofiling Limited
    Inventors: Suzanne Dilly, Gregory Stoloff, Paul Taylor
  • Patent number: 9579336
    Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: February 28, 2017
    Assignee: N.V. Nutricia
    Inventors: Mattheus Cornelis De Wilde, Johannes Wilhelmus Christina Sijben, Patrick Joseph Gerardus Hendrikus Kamphuis, Robert Johan Joseph Hageman
  • Patent number: 9546994
    Abstract: The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric m
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: January 17, 2017
    Assignees: Helmholtz Zentrum Munchen-Deutsches Forschungszentrum fur Geseundheit und Umwelt (GmbH), Deutsche Diabetes-Forschungsgesellschaft e.V.—Trager des Deutschen Diabetes-Zentrums Dusseldorf, Eberhard Karls Universitat Tubingen, Medizinische Fakultat
    Inventors: Wolfgang Rathmann, Christian Herder, Thomas Illig, Jerzy Adamski, Rui Wang-Sattler, Zhongao Yu, H.-Erich Wichmann, Hans-Ulrich Haring, Michael Roden, Annette Peters, Christine Meisinger, Martin Hrabe De Angelis, Thomas Meitinger
  • Patent number: 9540301
    Abstract: Provided is a method of manufacturing a high quality phosphonocrotonic acid derivative. The present invention is a method of manufacturing a compound represented by the following Formula (3) by reacting a compound represented by the following Formula (1) with a compound represented by the following Formula (2), which comprises a treatment process using an acid or base. [in the formula, R1 represents a C1-6 linear or branched alkyl group that may be substituted by a C6-10 aryl group, a C2-6 linear or branched alkenyl group that may be substituted by a C6-10 aryl group, a C2-6 linear or branched alkynyl group that may be substituted by a C6-10 aryl group, or a C6-10 aryl group, R2 represents a hydrogen atom, or a C1-6 linear or branched alkyl group that may be substituted by a C6-10 aryl group, R3 represents a C1-6 linear or branched alkyl group, a C6-10 aryl group, or a halogen atom, and X represents a halogen atom, and multiple R1s may be the same or different].
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: January 10, 2017
    Assignees: KOWA COMPANY, LTD., MANAC Incorporated
    Inventors: Shinji Ina, Takahiro Yamazaki, Junichi Sakata, Koji Ezaki, Katsuhiro Sakamoto